Atezolizumab plus Bevacizumab: A Novel Breakthrough in Hepatocellular Carcinoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33472912.
- Also identified by DOI 10.1158/1078-0432.CCR-20-4706 and PMC identifier 12951730.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The combination of atezolizumab and bevacizumab increases overall survival compared with sorafenib in advanced hepatocellular carcinoma (HCC). Its approval by the FDA has launched a new era of combination therapies in advanced and earlier settings that are likely to reshape the management of HCC across all disease stages.<i>See related article by Casak et al., p. 1836</i>.
Medical subject headings
- Carcinoma, Hepatocellular
- Liver Neoplasms